证券代码：605033 证券简称：美邦股份 公告编号：2023-058 陕西美邦药业集团股份有限公司 关于 2023 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责 任。 根据有关法律法规的规定，遵循规范、安全、高效、透明的原则，公司制 定了《募集资金管理办法》，对募集资金的存储、审批、使用、管理与监督做 出了明确的规定，以在制度上保证募集资金的规范使用。 单位：人民币万元 2021 年 9 月，本公司与西安银行股份有限公司雁塔支行、中国光大银行股 份有限公司西安分行营业部、招商银行股份有限公司西安南大街支行、中信银 1 根据上海证券交易所《上海证券交易所上市公司自律监管指引第1号 —— 规范运作》和《上海证券交易所上市公司自律监管指南第1号——公告格式》的 规定，将陕西美邦药业集团股份有限公司（以下简称"本公司"或"公司"）2023 年半年度募集资金存放与使用情况报告如下： 行股份有限公司西安分行、中国农业银行有限公司蒲城县支行和光大证券股份 有限公司（以下简称"光大证券"） ...

独立董事关于对公司第二届董事会第二十四次会议相关事项的 独立意见 根据中国证监会《上市公司独立董事规则》等法律法规、规范性文件以及《独 立董事工作制度》的规定，我们作为陕西美邦药业集团股份有限公司（以下简称 "公司"）的独立董事，对公司第二届董事会第二十四次会议审议的相关事项进行 了认真审议并发表如下独立意见: 一、独立董事对《关于公司 2023 年半年度募集资金存放与实际使用情况专 项报告的议案》的独立意见 陕西美邦药业集团股份有限公司 公司 2023 年半年度募集资金的存放和使用符合中国证监会、上海证券交易 所关于上市公司募集资金存放和使用的相关监管要求和管理办法,不存在募集资 金存放和使用违规的情形。公司所披露的募集资金存放和使用情况信息与实际情 况一致，如实履行了信息披露义务。 我们同意《公司 2023 年半年度募集资金存放与实际使用情况专项报告》。 (以下无正文) （本页无正文，为《陕西美邦药业集团股份有限公司独立董事关于对公司第二届 董事会第二十四次会议相关事项的独立意见》签署页 ) 蒋德权 2023 年 8 月 28 日 2 : （本页无正文，为《陕西美邦药业集团股份有限公司独立董事关于对公司第 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 344,708,419.69, a decrease of 29.30% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 69,276,052.01, down 24.50% year-on-year[5]. - The basic earnings per share decreased to CNY 0.51, reflecting a decline of 24.50%[6]. - The company reported a net profit margin of 24.7% for Q1 2023, compared to 25.8% in Q1 2022[20]. - In Q1 2023, the company's net profit was CNY 69,276,052.01, a decrease of 24.6% compared to CNY 91,752,261.05 in Q1 2022[22]. - Operating profit for Q1 2023 was CNY 79,271,153.70, down from CNY 106,982,851.88 in the same period last year, reflecting a decline of 26.0%[22]. - The total profit for Q1 2023 was CNY 79,946,102.29, down from CNY 106,934,436.60 in Q1 2022, reflecting a decrease of 25.2%[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,437,247,389.95, a decrease of 7.90% from the end of the previous year[6]. - Total assets as of March 31, 2023, were RMB 1,437,247,389.95, down from RMB 1,560,494,842.26 at the end of 2022, a decrease of 7.9%[18]. - Total liabilities decreased to RMB 281,618,625.34 from RMB 474,142,129.66, a significant reduction of 40.7%[18]. - The equity attributable to shareholders increased to RMB 1,155,628,764.61 from RMB 1,086,352,712.60, an increase of 6.4%[19]. Cash Flow and Investments - Cash flow from operating activities was negative at CNY -62,936,566.19, indicating a significant cash outflow[5]. - The cash flow from operating activities in Q1 2023 was negative at CNY -62,936,566.19, an improvement from CNY -81,768,900.40 in Q1 2022[25]. - Investment activities generated a net cash outflow of CNY -2,593,704.84 in Q1 2023, compared to a net inflow of CNY 13,871,427.04 in Q1 2022[25]. - The company reported cash and cash equivalents at the end of Q1 2023 amounting to CNY 242,286,396.44, up from CNY 91,338,101.17 at the end of Q1 2022[26]. Receivables and Inventory - Accounts receivable increased by 62.84%, primarily due to the timing of customer settlements[10]. - Accounts receivable increased to RMB 302,507,518.83 from RMB 185,766,247.94, reflecting a growth of 62.9%[17]. - Inventory decreased to RMB 331,957,925.01 from RMB 457,288,782.73, a reduction of 27.4%[17]. Expenses and Cost Management - The company experienced a 54.50% reduction in selling expenses, reflecting cost-cutting measures[10]. - Total operating costs for Q1 2023 were RMB 259,802,086.69, down 28.2% from RMB 361,683,622.68 in Q1 2022[20]. - Research and development expenses in Q1 2023 were CNY 19,925,881.93, a decrease of 22.3% from CNY 25,662,200.89 in Q1 2022[22]. - The company incurred sales expenses of CNY 21,956,508.77 in Q1 2023, compared to CNY 48,255,591.69 in Q1 2022, indicating a reduction of 54.4%[22]. Future Outlook - The company plans to focus on expanding its market presence and developing new products in the upcoming quarters[20].

证券代码：605033 证券简称：美邦股份 公告编号：2023-036 陕西美邦药业集团股份有限公司 关于举办2022年度业绩说明会暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 如有董事对临时公告内容的真实性、准确性和完整性无法保证或存在异议 的，公司应当在公告中作特别提示。 重要内容提示： 一、说明会类型 陕西美邦药业集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 20 日 在上海证券交易所网站（www.sse.com.cn）披露了《陕西美邦药业集团股份有限 会议召开时间：2023 年 05 月 05 日（星期五）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会议问题征集：投资者可于 2023 年 05 月 05 日 前 访 问 网 址 https://eseb.cn/148lqN4uW7S 或使用微信扫描下方小程序码进行会前提问， 公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注 的问题进行回答。 会议 ...

Financial Performance - The company's operating revenue for 2022 was CNY 906,045,600.11, representing a year-on-year increase of 7.54% compared to CNY 842,490,330.97 in 2021[22]. - The net profit attributable to shareholders of the listed company reached CNY 145,088,329.38, an increase of 15.38% from CNY 125,742,881.24 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 131.48 million, up 18.39% from the previous year[34]. - The basic earnings per share for 2022 was CNY 1.07, down 6.14% from CNY 1.14 in 2021[24]. - The weighted average return on equity decreased to 14.13%, down 6.48 percentage points from 20.61% in the previous year[24]. - The company reported a net profit of CNY 91,752,261.05 in the first quarter of 2022, with a significant drop in the third quarter resulting in a loss of CNY 5,200,157.13[26]. - The total net assets attributable to shareholders of the listed company increased to CNY 1,086,352,712.60, a rise of 12.35% from CNY 966,952,383.22 in 2021[23]. - The company maintained a total asset value of 1.56 billion yuan and net assets attributable to shareholders of 1.09 billion yuan[58]. - The company achieved operating revenue of 906.05 million yuan, a year-on-year increase of 7.54%[58]. - Net profit attributable to shareholders was 145.09 million yuan, up 15.38% compared to the previous year[58]. - The net cash flow from operating activities increased by 216.24%, amounting to CNY 126,411,753.13, primarily due to a decrease in raw material prices and reduced procurement expenditures[24]. Dividends and Shareholder Returns - The company plans to distribute cash dividends of 2.20 CNY per 10 shares, totaling 29,744,000 CNY for the year 2022[5]. - The cash dividend ratio accounts for 20.5% of the net profit attributable to shareholders of the listed company for the fiscal year 2022[181]. - The remaining undistributed profit amounts to CNY 443,399,115.99[177]. - The cash dividend distribution plan requires approval from the shareholders' meeting before implementation[177]. - The company has established a cash dividend policy that complies with its articles of association and shareholder resolutions[178]. - The independent directors have fulfilled their responsibilities regarding the cash dividend policy[178]. - The cash dividend distribution is fully funded from the company's undistributed profits[181]. - The company has proposed a three-year dividend return plan for shareholders from 2022 to 2024[148]. Research and Development - The company invested CNY 80.04 million in R&D, a 25.45% increase year-on-year, representing 8.83% of operating revenue[37]. - The company has established partnerships with several universities for research and development, focusing on new products in the fields of fungicides and insecticides[93]. - The company has achieved significant results in reducing waste emissions and improving production capacity and quality in pesticide formulation development[90]. - The company emphasizes the importance of technology innovation and has implemented various management systems to enhance R&D capabilities[92]. - The company plans to enhance its research and development capabilities by establishing a national-level technology center and a postdoctoral research station, focusing on new products and formulations to meet diverse market demands[123]. Market Position and Strategy - The company is constructing two key projects: a 30,000-ton new green pesticide formulation and water-soluble fertilizer production line, and a 20,000-ton pesticide raw material and intermediate production base[36]. - The company is focusing on the development of high-efficiency, low-toxicity pesticide products in response to national policies promoting green agriculture[79]. - The company has established itself as a leading enterprise in the pesticide formulation industry, recognized as a key agricultural industrialization leading enterprise in Shaanxi Province[86]. - The company has been ranked among the top 20 in China's pesticide industry formulation sales for four consecutive years, placing 15th in 2022[86]. - The company aims to enhance its competitiveness and profitability through continuous innovation and product updates[49]. - The company plans to deepen its presence in the pesticide market, leveraging successful marketing experiences and expanding its marketing network to enhance brand influence and market penetration[125]. Environmental and Sustainability Initiatives - The company is responding to national low-carbon policies and focusing on sustainable development through energy-saving and emission-reduction initiatives[39]. - The company is committed to environmental sustainability by developing efficient, low-toxicity pesticide formulations that align with market trends[130]. - The company achieved compliance with emission standards for both waste gas and wastewater during the reporting period, with average waste gas pollutant concentrations of VOC at 6.85 mg/m³ and COD in wastewater at 149.3 mg/L[194]. - The company has a valid pollution discharge permit until December 27, 2025, issued by the Weinan Ecological Environment Bureau, with major pollutants including waste gas and wastewater[193]. - The company conducted an emergency drill for environmental incidents during the reporting period, with the plan reviewed and filed with the local environmental bureau[197]. Corporate Governance and Management - The company held two shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[138]. - The board of directors convened 11 meetings, with independent directors providing independent opinions on major decisions[140]. - The company has established an investor relations management system to ensure timely and accurate communication with investors[144]. - The company has implemented a restricted stock incentive plan to align the interests of management with shareholders[150]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.74 million yuan[158]. - Zhang Shaowu resigned as General Manager due to work adjustments, and Zhang Tong was appointed as the new General Manager effective July 18, 2022[159]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[8]. - The company aims to establish a robust risk management framework to ensure compliance and operational efficiency while enhancing overall safety and quality standards[128]. - The company has implemented measures to mitigate raw material price risks, including centralized purchasing during price increases and enhancing supplier relationships[131]. - The company has not experienced any major safety or environmental incidents but acknowledges potential risks from equipment failures or operational issues[135].

证券代码：605033 证券简称：美邦股份 编号：2022 -05-10 陕西美邦药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|-----------------------------|-------------------------------------------------------------------------------------------------------------| | | | | | | ☐ 特定对象调研 | ☐ 分析师会议 | | 投资者关系 | ☐ 媒体采访 | 业绩说明会 | | 活动类别 | ☐ 新闻发布会 | ☐ 路演活动 | | | ☐ 现场参观 | | | | ☐ | 其他（请文字说明其他活动内容） | | 形式 | ☐ 现场 网上 | ☐ 电话会议 | | 参与单位名称 及人员姓名 | 2021 | 年度业绩说明会暨现金分红说明会线上参加人员 | | 时间 | 2022 年 05 月 10 日 | 15:00-16:00 | | 地点 | 价值在线（ www.i ...

2022 年第三季度报告 证券代码：605033 证券简称：美邦股份 陕西美邦药业集团股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 2022 年第三季度报告 | 经营活动产生的现 | 不适用 不适用 | | | -25,016,421.51 | | 89.23% | | | --- | --- | --- | --- | --- | --- | --- | --- | | 金流量净额 | | | | | | | | | 基本每股收益（元/ | -0.04 | | 32.57% | 0.82 | | 30.98% | | | 股） | | | | | | | ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 617,645,692.70, representing a 29.71% increase compared to CNY 476,180,685.58 in the same period last year[22]. - The net profit attributable to shareholders of the listed company reached CNY 116,975,137.45, a significant increase of 68.45% from CNY 69,440,443.35 year-on-year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 106,270,404.13, up 55.47% from CNY 68,352,970.35 in the previous year[22]. - Basic earnings per share rose by 27.94% to CNY 0.87 compared to the same period last year[24]. - Net profit attributable to shareholders increased by 68.45%, driven by expanded sales and increased government subsidies[24]. - The company achieved operating revenue of 617,645,692.70 CNY, a year-on-year increase of 29.71%[52]. - Net profit attributable to shareholders reached 11,697.51 million CNY, up 68.45% compared to the same period last year[52]. - The company reported a significant increase in revenue for the first half of 2022, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 15%[119]. Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -111,749,127.85, an improvement of 35.55% compared to CNY -173,380,608.93 in the same period last year[22]. - The total assets decreased by 0.81% to CNY 1,451,549,098.91 compared to the end of the previous year[23]. - The total current assets as of June 30, 2022, amounted to RMB 1,170,222,860.37, a decrease from RMB 1,192,777,686.41 at the beginning of the period[149]. - Cash and cash equivalents decreased to RMB 242,586,895.69 from RMB 254,387,561.65[149]. - Accounts receivable increased significantly to RMB 402,815,374.47 from RMB 90,143,475.22, indicating a substantial rise in credit sales[149]. - The total cash inflow from financing activities was CNY 130,701,980.00, compared to CNY 52,717,080.00 in the same period last year, indicating an increase of approximately 147.5%[166]. Research and Development - In the first half of 2022, the company's R&D expenses amounted to 37.84 million yuan, accounting for 6.13% of its operating revenue, indicating a commitment to innovation[43]. - Research and development expenses increased by 33.13% to 37,842,804.61 CNY, reflecting a commitment to innovation[53]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[113]. - The company emphasizes R&D investment to develop efficient, low-toxicity, and environmentally friendly pesticide formulations to achieve product differentiation[66]. Market Position and Strategy - The company is positioned among the top 20 pesticide formulation manufacturers in China, indicating strong market competitiveness[30]. - The company ranked 15th in the national pesticide industry formulation sales TOP100 in 2022, reflecting its strong market position[37]. - The company plans to continue focusing on its core business while expanding product categories and business channels to enhance competitiveness[34]. - The agricultural chemical industry is experiencing increased demand and price growth due to global food security concerns, benefiting domestic pesticide manufacturers[50]. - The company has implemented a strategy focusing on core crops and pest control solutions, leading to steady performance improvement despite external challenges[37]. Environmental Compliance - The company’s environmental management system has been certified to meet the GB/T24001-2016/ISO14001:2015 standards, ensuring compliance with environmental regulations[80]. - The company holds a valid Pollutant Discharge Permit until December 27, 2025, with major pollutants including waste gas and wastewater[81]. - The company achieved compliance with pollutant discharge standards for both waste gas and wastewater during the reporting period[82]. - The company has implemented effective pollution control measures, including UV photolysis and activated carbon adsorption for waste gas treatment[83]. - No significant violations of environmental laws or regulations occurred during the reporting period, nor were there any environmental pollution accidents[96]. Future Outlook - The company expects a revenue growth of 10% for the second half of 2022, projecting total revenue to reach approximately 3.3 billion RMB for the full year[114]. - New product launches are anticipated to contribute an additional 500 million RMB in revenue by the end of 2022[112]. - Market expansion plans include entering two new provinces, which are expected to increase market share by 5%[114]. - The company has committed to maintaining a dividend payout ratio of 30% of net profits for the fiscal year[114]. Shareholder and Governance - The company has committed to minimizing investor losses and will submit proposals for shareholder approval[122]. - The company assures that all shareholders possess the necessary legal qualifications to hold shares, with no violations of regulations regarding shareholding[123]. - The company will not distribute profits to shareholders who fail to fulfill public commitments[121]. - The company has established measures to avoid conflicts of interest among its major shareholders and actual controllers[123].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 487,555,601.85, representing a year-on-year increase of 77.56%[5] - The net profit attributable to shareholders for the same period was CNY 91,752,261.05, up 96.99% compared to the previous year[5] - Basic and diluted earnings per share were both CNY 0.68, reflecting a growth of 47.53% year-on-year[6] - The total profit for Q1 2022 was ¥106,934,436.60, up from ¥54,957,683.45 in the same period last year, indicating a growth of 94.3%[20] - The operating profit for Q1 2022 reached ¥106,982,851.88, compared to ¥54,724,946.64 in Q1 2021, reflecting an increase of 95.5%[22] - The net profit attributable to shareholders of the parent company for Q1 2022 was ¥91,752,261.05, compared to ¥46,576,192.23 in Q1 2021, representing an increase of 96.7%[20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,446,430,467.04, a decrease of 1.16% from the end of the previous year[6] - Total assets as of March 31, 2022, were ¥1,446,430,467.04, slightly down from ¥1,463,381,113.31 at the end of 2021[16] - Total liabilities decreased to ¥387,725,822.77 from ¥496,428,730.09, a decline of 22%[16] - The company's equity attributable to shareholders increased to ¥1,058,704,644.27 from ¥966,952,383.22, reflecting a growth of 9.5%[16] Cash Flow - The company's cash flow from operating activities was negative at CNY -81,768,900.40, indicating a significant cash outflow[5] - The cash flow from operating activities for Q1 2022 was a net outflow of ¥81,768,900.40, an improvement from a net outflow of ¥126,499,568.84 in Q1 2021[22] - The cash flow from investing activities generated a net inflow of ¥13,871,427.04 in Q1 2022, compared to a net outflow of ¥33,019,410.87 in Q1 2021[23] - The total cash and cash equivalents at the end of Q1 2022 were ¥91,338,101.17, significantly up from ¥19,793,671.70 at the end of Q1 2021[23] Expenses - Total operating costs for Q1 2022 were ¥361,683,622.68, up 71.8% from ¥210,667,507.00 in Q1 2021[18] - Research and development expenses rose by 94.81%, reflecting increased investment in R&D[7] - Research and development expenses for Q1 2022 were ¥25,662,200.89, up from ¥13,173,234.98 in Q1 2021, marking a rise of 94.5%[22] - The company reported a significant increase in sales expenses by 205.31%, attributed to higher sales activities[7] - The company reported a decrease in financial expenses, with interest expenses of ¥151,987.12 in Q1 2022, compared to ¥112,152.77 in Q1 2021, indicating a rise of 35.4%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,797[9] Market Strategy - The company is focusing on expanding its market presence and enhancing product development, although detailed strategies were not specified in the report[18]

Financial Performance - The company's operating revenue for 2021 was CNY 842,490,330.97, representing a 48.19% increase compared to CNY 568,518,122.56 in 2020[22] - The net profit attributable to shareholders for 2021 was CNY 125,742,881.24, a 59.71% increase from CNY 78,734,291.94 in the previous year[22] - The net profit after deducting non-recurring gains and losses was CNY 111,061,265.71, up 48.82% from CNY 74,630,108.05 in 2020[22] - The net cash flow from operating activities was negative CNY 108,753,545.63, a decrease of 245.25% compared to CNY 74,875,302.08 in 2020[22] - The net assets attributable to shareholders increased by 115.18% to approximately CNY 966.95 million compared to the end of 2020[23] - Total assets rose by 86.21% to approximately CNY 1.46 billion compared to the end of 2020[23] - Basic earnings per share increased by 46.15% to CNY 1.14 from CNY 0.78 in 2020[24] - The gross profit margin improved by 1.73 percentage points to 38.29%, driven by higher sales of new products[66] - The company reported a significant increase in financing activities, with net cash flow from financing activities reaching CNY 350.59 million, a rise of 687.26%[63] Dividend and Shareholder Information - The company plans to distribute a cash dividend of CNY 1.9 per 10 shares, totaling CNY 25,688,000.00 based on a total share capital of 135,200,000 shares[5] - The total number of shares held by the board members remained unchanged at 76,000,000 shares throughout the reporting period[154] - The total pre-tax remuneration for the board members amounted to 4.97 million yuan, with individual remuneration ranging from 19.6 thousand to 75 thousand yuan[154] - The company has not proposed any cash profit distribution plan despite having positive distributable profits, indicating a focus on reinvestment[179] Risk Management and Compliance - The company has not reported any significant risks that could materially affect its operations during the reporting period[8] - The company emphasizes the importance of understanding the risks associated with forward-looking statements regarding future development plans and strategies[6] - The company has maintained a high level of transparency in information disclosure, adhering to the regulations set forth by the China Securities Regulatory Commission[148] - The company has developed a comprehensive internal control mechanism to enhance governance and risk management awareness among its directors and senior management[149] - The company has not encountered any significant differences in governance compared to the regulations set by the China Securities Regulatory Commission[149] Research and Development - Research and development expenses amounted to 63.81 million yuan, a 24.22% increase year-on-year, representing 7.57% of total revenue[38] - The number of R&D personnel was 186, accounting for 20.02% of the total workforce[73] - The company has established partnerships with several universities, including China Agricultural University and Zhejiang University, to enhance its R&D capabilities in pesticide products[97] - The company has implemented a multi-departmental approach to its R&D innovation process, ensuring that market demands guide product development[94] - The company aims to enhance its market competitiveness by increasing R&D investment and developing new products, focusing on high-efficiency, low-toxicity, and environmentally friendly products[123] Market Position and Strategy - The company aims to enhance its market position by focusing on high-quality development and expanding its agricultural protection product line[34] - The company has been ranked among the top 20 in China's pesticide industry formulation sales for four consecutive years since 2017[47] - The company emphasizes a dual-drive strategy of raw pesticide and formulation integration, aiming for both domestic and international market expansion[51] - The company has established a nationwide marketing channel, enhancing its ability to reach diverse agricultural regions[57] - The company is committed to establishing a modern active ingredient production base to strengthen its position in the agricultural supply chain[125] Environmental Responsibility - The company has implemented effective pollution control measures, achieving compliance with emission standards for waste gas and wastewater during the reporting period[188] - The company has a valid pollution discharge permit until December 27, 2025, and has established a comprehensive risk management system[187] - The company has implemented effective comprehensive treatment measures for waste water, waste gas, waste residue, and noise, and has obtained the environmental management system certification[196] - The company has not experienced any major violations of environmental laws or regulations, nor any pollution accidents during the reporting period[194] Corporate Governance - The board of directors convened 15 meetings, with a composition of 9 members, including 3 independent directors, adhering to relevant laws and regulations[145] - The supervisory board conducted 7 meetings, effectively overseeing the company's management and financial status[147] - The company has established an independent financial accounting department and a strict financial management system, ensuring no shared bank accounts with controlling shareholders[151] - The company has a complete and independent business system, with no interference from controlling shareholders in its operations[151] Employee and Management Structure - The company employed a total of 933 staff members, with 346 in the parent company and 587 in major subsidiaries[172] - The workforce includes 220 production personnel, 433 sales personnel, 186 technical personnel, 27 financial personnel, and 67 administrative personnel[172] - The company is enhancing its talent development plan by establishing a structured talent pipeline and focusing on training to improve management and technical skills[131] - The company has a diverse management team with experience in various sectors, including agriculture, finance, and pharmaceuticals[156] Challenges and Market Conditions - The company faced challenges due to rising raw material prices and implemented strategies to minimize procurement costs[46] - The company recognizes the seasonal nature of its business, with peak pesticide demand typically occurring from March to September, and is working to mitigate the impact of this seasonality on cash flow management[138] - The company faces market competition risks due to a large number of small-scale pesticide producers and a lack of strong R&D capabilities, leading to product homogeneity and price-based competition[135]